SGN STNV
Alternative Names: SGN-STNV; STn-VedotinLatest Information Update: 29 Mar 2024
At a glance
- Originator Seagen
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunotoxins
- Mechanism of Action Microtubule protein inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 15 Mar 2024 SGN STNV is still in phase-I development in Solid-tumours (Late-stage disease, Second-line therapy or greater) in USA (IV)
- 15 Mar 2024 Seagen terminates a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA, United Kingdom, Spain, Italy, France, Canada (IV) due to portfolio prioritization (NCT04665921)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV)